亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

濟(jì)南立德醫(yī)藥技術(shù)有限公司  

化學(xué)原料及醫(yī)藥中間體

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人:李倩
  • 電話:400-0926006
  • QQ:3003423629
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
非那雄胺
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
過(guò)期 長(zhǎng)期有效
更新 2018-11-29 12:30
 
詳細(xì)信息
 中文名稱:非那雄胺

 

中文別名:N-叔丁基-3-氧代-4-氮雜-5α-雄甾-1-烯-17β-甲酰胺; 非那甾胺;保列治;非那利得;保利治

英文名稱:finasteride

英文別名:Finastid;Propecia;Finpecia;N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide;Finasteride;Proscar;MK 906

CAS號(hào):98319-26-7

分子式:C23H36N2O2
 作用:前列腺增生、男性脫發(fā)

©2025 濟(jì)南立德醫(yī)藥技術(shù)有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:2974  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |